Prokaryotics, Inc.
Publicly observedUnion, United States
Seen in a public record (e.g. a government grant database); not otherwise verified.
Details and provenance
| Item | Value | Source | Status |
|---|---|---|---|
| Country | US | NIH RePORTER (opens in a new tab) 28 Sept 2026 | Publicly observed |
| City / locality | Union | NIH RePORTER (opens in a new tab) 28 Sept 2026 | Publicly observed |
| Name | Prokaryotics, Inc. | NIH RePORTER (opens in a new tab) 28 Sept 2026 | Publicly observed |
| UEI (U.S. federal entity ID) | CBKMWXFE94Z4 | NIH RePORTER (opens in a new tab) 28 Sept 2026 | Publicly observed |
Recorded events
- Grant19 Sept 2025Publicly observed
NIH SBIR/STTR award: Development of an active site inhibitor of Fks1 as a broad spectrum antifungal agent
USD 299,697.00 · National Institute of Allergy and Infectious Diseases · Source: NIH RePORTER (opens in a new tab)
- Grant1 Sept 2022Publicly observed
NIH SBIR/STTR award: Development of a mechanistically novel synergistic adjuvant to partner with polymyxin antibiotics
USD 977,454.00 · National Institute of Allergy and Infectious Diseases · Source: NIH RePORTER (opens in a new tab)
- Grant1 Sept 2022Publicly observed
NIH SBIR/STTR award: Development of a mechanistically novel synergistic adjuvant to partner with polymyxin antibiotics
USD 996,450.00 · National Institute of Allergy and Infectious Diseases · Source: NIH RePORTER (opens in a new tab)
Information only — not investment advice or an endorsement. Is this your company? Submit or update its details or request a correction.